Arcus Biosciences RCUS Accretion (Amortization) of Discounts and Premiums, Investments
Accretion (Amortization) of Discounts and Premiums, Investments at other companies
Other financials
Where this comes from
Reported directly by Arcus Biosciences in its filing.
Tagged under the XBRL concept us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments.
The official record: Arcus Biosciences’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Arcus Biosciences's accretion (amortization) of discounts and premiums, investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Arcus Biosciences's accretion (amortization) of discounts and premiums, investments?
- Arcus Biosciences (RCUS) reported accretion (amortization) of discounts and premiums, investments of $3M in Q1 2026.
- How has Arcus Biosciences's accretion (amortization) of discounts and premiums, investments changed year-over-year?
- Arcus Biosciences's accretion (amortization) of discounts and premiums, investments decreased by 25.0% year-over-year, from $4M to $3M.
- What is the long-term trend for Arcus Biosciences's accretion (amortization) of discounts and premiums, investments?
- Over 3 years (2021 to 2025), Arcus Biosciences's accretion (amortization) of discounts and premiums, investments has grown at a 37.5% compound annual growth rate (CAGR), from -$5M to $13M.
- What does accretion (amortization) of discounts and premiums, investments mean?
- This metric captures the periodic adjustment to the carrying value of investment securities to reflect the amortization of premiums or the accretion of discounts over the life of the instrument. It reconciles the difference between the purchase price and the face value of debt securities held in the investment portfolio. This adjustment is essential for accurately reflecting the effective interest income earned on cash equivalents and marketable securities.